180 related articles for article (PubMed ID: 37125560)
1. Brain Magnetic Resonance Imaging (MRI) in Spinal Muscular Atrophy: A Scoping Review.
Mugisha N; Oliveira-Carneiro A; Behlim T; Oskoui M
J Neuromuscul Dis; 2023; 10(4):493-503. PubMed ID: 37125560
[TBL] [Abstract][Full Text] [Related]
2. The spinal and cerebral profile of adult spinal-muscular atrophy: A multimodal imaging study.
Querin G; El Mendili MM; Lenglet T; Behin A; Stojkovic T; Salachas F; Devos D; Le Forestier N; Del Mar Amador M; Debs R; Lacomblez L; Meininger V; Bruneteau G; Cohen-Adad J; Lehéricy S; Laforêt P; Blancho S; Benali H; Catala M; Li M; Marchand-Pauvert V; Hogrel JY; Bede P; Pradat PF
Neuroimage Clin; 2019; 21():101618. PubMed ID: 30522974
[TBL] [Abstract][Full Text] [Related]
3. Cerebellar degeneration in adult spinal muscular atrophy patients.
de Borba FC; Querin G; França MC; Pradat PF
J Neurol; 2020 Sep; 267(9):2625-2631. PubMed ID: 32388834
[TBL] [Abstract][Full Text] [Related]
4. Cross-sectional and longitudinal assessment of the upper cervical spinal cord in motor neuron disease.
van der Burgh HK; Westeneng HJ; Meier JM; van Es MA; Veldink JH; Hendrikse J; van den Heuvel MP; van den Berg LH
Neuroimage Clin; 2019; 24():101984. PubMed ID: 31499409
[TBL] [Abstract][Full Text] [Related]
5. Brain, cognition, and language development in spinal muscular atrophy type 1: a scoping review.
Masson R; Brusa C; Scoto M; Baranello G
Dev Med Child Neurol; 2021 May; 63(5):527-536. PubMed ID: 33452688
[TBL] [Abstract][Full Text] [Related]
6. Drug treatment for spinal muscular atrophy type I.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
[TBL] [Abstract][Full Text] [Related]
7. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
Hoy SM
CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
[TBL] [Abstract][Full Text] [Related]
8. Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management.
Paracha N; Hudson P; Mitchell S; Sutherland CS
Pharmacoeconomics; 2022 Apr; 40(Suppl 1):11-38. PubMed ID: 34761360
[TBL] [Abstract][Full Text] [Related]
9. Severe brain involvement in 5q spinal muscular atrophy type 0.
Mendonça RH; Rocha AJ; Lozano-Arango A; Diaz AB; Castiglioni C; Silva AMS; Reed UC; Kulikowski L; Paramonov I; Cuscó I; Tizzano EF; Zanoteli E
Ann Neurol; 2019 Sep; 86(3):458-462. PubMed ID: 31301241
[TBL] [Abstract][Full Text] [Related]
10. Muscle impairment in MRI affect variability in treatment response to nusinersen in patients with spinal muscular atrophy type 2 and 3: A retrospective cohort study.
Shimizu-Motohashi Y; Chiba E; Mizuno K; Yajima H; Ishiyama A; Takeshita E; Sato N; Oba M; Sasaki M; Ito S; Komaki H
Brain Dev; 2023 Mar; 45(3):161-170. PubMed ID: 36460551
[TBL] [Abstract][Full Text] [Related]
11. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
[TBL] [Abstract][Full Text] [Related]
12. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
[TBL] [Abstract][Full Text] [Related]
13. Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA).
Paracha N; Hudson P; Mitchell S; Sutherland CS
Pharmacoeconomics; 2022 Apr; 40(Suppl 1):69-89. PubMed ID: 34658008
[TBL] [Abstract][Full Text] [Related]
14. Partial restoration of cardio-vascular defects in a rescued severe model of spinal muscular atrophy.
Shababi M; Habibi J; Ma L; Glascock JJ; Sowers JR; Lorson CL
J Mol Cell Cardiol; 2012 May; 52(5):1074-82. PubMed ID: 22285962
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic and molecular insights into spinal muscular atrophy due to mutations in BICD2.
Rossor AM; Oates EC; Salter HK; Liu Y; Murphy SM; Schule R; Gonzalez MA; Scoto M; Phadke R; Sewry CA; Houlden H; Jordanova A; Tournev I; Chamova T; Litvinenko I; Zuchner S; Herrmann DN; Blake J; Sowden JE; Acsadi G; Rodriguez ML; Menezes MP; Clarke NF; Auer Grumbach M; Bullock SL; Muntoni F; Reilly MM; North KN
Brain; 2015 Feb; 138(Pt 2):293-310. PubMed ID: 25497877
[TBL] [Abstract][Full Text] [Related]
16. Spinal muscular atrophy: survival pattern and functional status.
Chung BH; Wong VC; Ip P
Pediatrics; 2004 Nov; 114(5):e548-53. PubMed ID: 15492357
[TBL] [Abstract][Full Text] [Related]
17. Nusinersen treatment of spinal muscular atrophy - a systematic review.
Albrechtsen SS; Born AP; Boesen MS
Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
[TBL] [Abstract][Full Text] [Related]
18. Cardiac pathology in spinal muscular atrophy: a systematic review.
Wijngaarde CA; Blank AC; Stam M; Wadman RI; van den Berg LH; van der Pol WL
Orphanet J Rare Dis; 2017 Apr; 12(1):67. PubMed ID: 28399889
[TBL] [Abstract][Full Text] [Related]
19. Onasemnogene abeparvovec for the treatment of spinal muscular atrophy.
McMillan HJ; Proud CM; Farrar MA; Alexander IE; Muntoni F; Servais L
Expert Opin Biol Ther; 2022 Sep; 22(9):1075-1090. PubMed ID: 35437095
[TBL] [Abstract][Full Text] [Related]
20. Disrupted individual-level morphological brain network in spinal muscular atrophy types 2 and 3.
Li Y; Nie H; Xiang P; Shen W; Yan M; Yan C; Su S; Qian L; Liang Y; Tang W; Yang Z; Li Y; Chen Y
CNS Neurosci Ther; 2024 Jun; 30(6):e14804. PubMed ID: 38887183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
